The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Archive — May 2026
Page 5 of 5 of this archive, newest first.
Independent analysis puts a TFC semaglutide lot at 96.7%, against 94.6% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
Nantong export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
The mechanism behind the mechanism
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
Why people actually stop, in the order they actually stop
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.
Same material, different gradients, different answers
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
From the floor in Qingdao: 13 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
STEP 5 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.